[CAS NO. 69-52-3] Ampicillin sodium

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [69-52-3]

Catalog

HY-B0522A

Brand

MCE

CAS

69-52-3

DESCRIPTION [69-52-3]

Overview

MDL	MFCD00064313
Molecular Weight	371.38
Molecular Formula	C16H18N3NaO4S
SMILES	O=C([C@@H]1N(C2=O)[C@]([C@@H]2NC([C@@H](C3=CC=CC=C3)N)=O)([H])SC1(C)C)O[Na]

For research use only. We do not sell to patients.

12 Publications Citing Use of MCE

Summary

Ampicillin sodium (D-(-)-α-Aminobenzylpenicillin sodium salt) is a broad-spectrum beta-lactam antibiotic against a variety of gram-positive and gram-negative bacteria ^[1] .

IC50 & Target

β-lactam

In Vitro

Ampicillin inhibits the growth of E. coli of swine origin in a dose-dependent manner. The effective inhibitory concentration of Ampicillin was 2.5 uG/mL ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Ampicillin is very effective in alleviating the symptoms of hemorrhagic enteritis in a 11-week old pig ^[1] . Ampicillin produces maximum concentrations in bile twice as high as in serum. The peak concentration of ampicillin after an oral dose is as twice as high in portal blood as in peripheral blood ^[2] . Ampicillin provides neuroprotection against ischemia-reperfusion brain injury. Ampicillin reduces the activities of MMPs and increases the expression level of GLT-1. Pretreatment with ampicillin significantly reduces medial hippocampal cell death following global forebrain ischemia ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00021671	National Institute of Allergy and Infectious Diseases (NIAID)\|National Institute of Mental Health (NIMH)\|National Institute on Drug Abuse (NIDA)	HIV Infections		Phase 3
NCT01433757	University of Florida\|Tyler´s Hope for a Dystonia Cure, Inc	DYT-1\|Dystonia	September 2011	Phase 1
NCT01945450	Hadassah Medical Organization	Endometritis	January 2014	Not Applicable
NCT04041791	University of Oxford\|University of Nairobi\|London School of Hygiene and Tropical Medicine\|National Institute for Health Research, United Kingdom\|Department for International Development, United Kingdom\|Medical Research Council\|Wellcome Trust\|Kenya Ministry of Health	Pneumonia	August 19, 2019	Phase 3
NCT03997266	Michael Morowitz\|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)\|University of Pittsburgh	Microbial Colonization\|Extreme Prematurity\|Early-Onset Neonatal Sepsis\|Late-Onset Neonatal Sepsis\|Necrotizing Enterocolitis of Newborn\|Death; Neonatal	August 5, 2020	Phase 4
NCT00814905	United States Naval Medical Center, Portsmouth	Chorioamnionitis	June 2009	Not Applicable
NCT01189487	Pfizer	Pneumonia, Bacterial	October 2010	Phase 3
NCT02819570	Western Galilee Hospital-Nahariya	Premature Rupture of Membrane	November 2015	Phase 4
NCT02427932	Stanford University\|David Drover, MD	Drug Metabolism During Pregnancy	May 2015
NCT02865564	University Medical Centre Ljubljana\|University of Ljubljana	Gastrointestinal Diseases\|Colic	November 2016	Not Applicable
NCT01994993	Michael Cohen-Wolkowiez\|The Emmes Company, LLC\|Duke University	Complicated Intra Abdominal Infections	December 2013	Phase 2\|Phase 3
NCT03060473	The University of Texas Medical Branch, Galveston	Preterm Premature Rupture of Membranes (PPROM)	February 23, 2017	Phase 3
NCT04202380	Assiut University	Preterm Pre-labor Rupture of Membranes	January 2020	Not Applicable
NCT01551394	PENTA Foundation\|Chiesi Farmaceutici S.p.A.	Sepsis	September 2012	Phase 3
NCT02007603	Medical University of Vienna	Infection During Hemodialysis	August 2013	Phase 3
NCT05051163	Makerere University	HIV-1-infection\|Malnutrition, Child	June 14, 2021	Phase 2\|Phase 3
NCT02477423	University of Chicago	Premature Birth of Newborn\|Enterocolitis, Necrotizing	July 2015	Not Applicable
NCT00491426	Duke University\|Pediatric Pharmacology Research Units Network	Infection	January 2006
NCT00002052	University of Southern California\|NIH AIDS Clinical Trials Information Service	HIV Infections\|Salmonella Infections		Not Applicable
NCT02829060	University of California, San Diego	Nephrolithiasis\|Urinary Tract Infection (UTI)\|Sepsis	January 2016	Not Applicable
NCT02384200	University of California, San Diego\|Mayo Clinic\|University of British Columbia\|The Cleveland Clinic\|Duke University\|Ohio State University\|Dartmouth-Hitchcock Medical Center\|Vanderbilt University\|New York University	Nephrolithiasis\|Urinary Tract Infections	March 2015	Phase 4
NCT02424734	Pfizer\|PRA Health Sciences	Late-onset Sepsis	August 4, 2015	Phase 2
NCT01633294	Hospital de Santa Maria, Portugal	Chorioamnionitis\|Puerperal Endometritis\|Neonatal Early Onset Sepsis\|Neonatal Meningitis\|Neonatal Pneumonia	October 2008	Phase 2\|Phase 3
NCT01312792	International Centre for Diarrhoeal Disease Research, Bangladesh\|UNICEF	Pneumonia	August 2010	Not Applicable
NCT03248973	Far Eastern Memorial Hospital	Listeria Monocytogenes	April 3, 2017
NCT05469984	Western Galilee Hospital-Nahariya	Preterm Labor With Preterm Delivery\|Premature Rupture of Membranes Prolonged	September 2022	Not Applicable

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

H ₂ O : ≥ 200 mg/mL ( 538.53 mM )

DMSO : 200 mg/mL ( 538.53 mM ; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.6927 mL	13.4633 mL	26.9266 mL
5 mM	0.5385 mL	2.6927 mL	5.3853 mL
10 mM	0.2693 mL	1.3463 mL	2.6927 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 50 mg/mL (134.63 mM); Clear solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 5 mg/mL (13.46 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 5 mg/mL (13.46 mM); Clear solution
4.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 5 mg/mL (13.46 mM); Clear solution
5.

Add each solvent one by one: 5% DMSO >> 40% PEG300 >> 5% Tween-80 >> 50% saline

Solubility: ≥ 2.5 mg/mL (6.73 mM); Clear solution
6.

Add each solvent one by one: 5% DMSO >> 95% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (6.73 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-, sodium salt (1:1), (2S,5R,6R)-

4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-(2-amino-2-phenylacetamido)-3,3-dimethyl-7-oxo-, monosodium salt, D-(-)-

4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[(aminophenylacetyl)amino]-3,3-dimethyl-7-oxo-, monosodium salt, [2S-[2α,5α,6β(S*)]]-

4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[(2R)-aminophenylacetyl]amino]-3,3-dimethyl-7-oxo-, monosodium salt, (2S,5R,6R)-

Ampicillin sodium

Penbritin S

Sodium P-50

Sodium 6-(2-amino-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate

Sodium 6-[D-α-aminophenylacetamido]penicillanoate

Sodium ampicillin

Ampicillin sodium salt

Binotal sodium

Sodium D-α-aminobenzylpenicillanate

Sodium binotal

D-α-Aminobenzylpenicillin sodium salt

Polycillin N

Monosodium ampicillin

Ampicillin-Na

Anhypen

Britapen injection

Sodium ampicillinate

Ampicin

Principen N

Omnipen N

Alpen N

Pen A/N

Amcill S

Pentrex

Cilleral

Ampi-Dry 5000

Solampi

Pamecil

Totacillin N